Report on one PhIII remdisivir study sends investors into overdrive

10 hours ago

Report on one PhIII remdisivir study sends investors into overdrive, adding billions to Gilead's market cap

Before any drug is officially proven effective against Covid-19, every data nugget surrounding an experimental treatment understandably arouses investors’ and patients’ hopes alike. Thursday night saw perhaps the most vivid and dramatic illustration to date.


Gilead shares $GILD soared 12.10% to $85.80 after STAT reported on one portion of the data from one of the company’s two ongoing Phase III trials for remdesivir. Of 125 patients recruited at the University of Chicago Medicine, 113 had severe disease and most of them have been discharged. Two deaths were recorded.

Is this is how you put a high case fatality rate back down to around 2 % ?

link

They make a lot of money hacking nature's remedies and making expensive meds that do the same thing.

I hope it works. If this works for viruses in general it could be a big step in helping mitigate the next big outbreak.